ClinicalTrials.gg
CompletedNCT00589875BrTK02Updated Apr 3, 2024Results posted

Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma

A Phase 2 interventional study of CAN-2409 and Valacyclovir in Malignant Glioma, Glioblastoma Multiforme and Anaplastic Astrocytoma, sponsored by Candel Therapeutics, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-03.

Primary conditionGlioblastomaRegistry: GliomaReclassifiedWhy we changed it
Registry
Glioma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glioblastoma
Why
  1. The study's listed conditions name Glioblastoma, a narrower term within Glioma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Candel Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 323 under way, 16 of them phase 3. Glioblastoma · United States.

Enrollment
377th of 1,155
52 · median 33
Started
2007
with 45 others
Phase 2
396 of 1,302
37 open now
Registered
287th of 1,302
by date

Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 377th largest by enrollment of the 1,155 interventional ones that give a count, is one of 46 that started in 2007, is one of 396 in phase 2, and was the 287th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 340 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,302 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the safety and potential efficacy of CAN-2409 (also known / previously described as AdV-tk, GMCI) for malignant gliomas. The approach used an adenoviral vector (disabled virus) engineered to express the Herpes thymidine kinase gene (aglatimagene besadenovec, CAN-2409), followed by an antiherpetic prodrug, valacyclovir. CAN-2409 was injected into the resection bed after standard tumor surgery and valacyclovir pills were taken for 14 days. Standard radiation and chemotherapy were administered which have been shown to work cooperatively with CAN-2409 + prodrug to kill tumor cells. The hypothesis is that this combination therapy can be safely delivered and will lead to improvement in the clinical outcome for patients with newly diagnosed malignant gliomas, including glioblastoma multiforme (WHO grade IV) and anaplastic astrocytomas (WHO grade III).

Read the detailed description

Patients had resectable or partially resectable malignant glioma and received injection of CAN-2409 into remaining tumor or tumor bed after resection. Pathologic confirmation of malignant glioma must be made prior to CAN-2409 injection; if this was not possible, the injection was not performed and the subject was no longer eligible for the study. The oral prodrug, valacyclovir, started 1-3 days after CAN-2409 injection and continued for 14 days. Standard radiotherapy began on average 7 days after CAN-2409 injection for the up-front course. Patients received temozolomide as per standard of care after completion of prodrug.

03

Conditions studied

  • Malignant Glioma
  • Glioblastoma Multiforme
  • Anaplastic Astrocytoma
  • High Grade Glioma

Browse trials for

Keywords

  • Immunotherapy
  • Cytotoxicity
  • Tumor vaccine
  • CAN-2409
  • AdV-tk
  • Candel Therapeutics, Inc.
04

In context

Glioblastoma Reclassified

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

This study's enrollment of 52 is above the median of 36 across 1,756 interventional studies indexed under Glioblastoma.

Browse Glioblastoma studies →

Lead sponsor

Candel Therapeutics, Inc. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.

Compared within Glioblastoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Glioma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have presumed resectable or partially resectable malignant glioma based on clinical and radiologic evaluation (pathologic confirmation of malignant glioma must be made at the time of surgery if not previously determined). Patients who have previously received CAN-2409 + prodrug on this study may receive an additional CAN-2409 + prodrug course at recurrence if eligibility criteria are still met.
  • Tumor must be accessible for injection and must not be located in the brainstem, midbrain, contained within the ventricular system, or located in an infratentorial location.
  • Upfront patients must be planning to undergo standard radiation therapy.
  • Patients must be 18 years of age or older.
  • Performance status must be ≥70.
  • Patients must have (AST) \< 3x .
  • Patients must have serum creatinine \< 2mg/dl and calculated >10ml/min.
  • Patients must have > 100,000/mm3 and WBC > 3000/mm3.
  • Patients of reproductive age must agree to use a medically accepted form of while on the study.
  • Patients must give study specific prior to enrollment. For re-administration, patients must be re-consented.
  • Patients must be able to tolerate MRI scan procedure

Exclusion criteria

Exclusion Criteria:

  • Active liver disease including cirrhosis or hepatitis
  • Patients on drugs (with exception of )
  • Known + patients.
  • Patients with acute infections (viral, bacterial or fungal infections requiring therapy).
  • Pregnant or breast feeding patients. Female patients of childbearing age must have negative serum or urine pregnancy test within 1 week of beginning therapy.
  • Evidence of disease or other (except squamous or basal cell skin cancers).
  • Other serious co-morbid illness or compromised organ function.
  • Patients may not receive chemotherapy until valacyclovir is completed and may not receive other anti-tumor agents within 30 days prior to study entry or during active participation in the study (defined as from CAN-2409 injection until tumor progression).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Single arm

    This study is an extension of evaluation of the surgical resection arm, Arm B, from a phase Ib study in which dose escalation on arm B was completed.

    Biological: CAN-2409 · Drug: Valacyclovir · Drug: Temozolomide · Radiation: Radiation therapy

Interventions

  • BiologicalCAN-2409

    Single dose of 3x10e11 vector particles of CAN-2409 delivered to the tumor bed after resection on day 0.

  • Single course of valacyclovir at dose of 2 grams orally three times per day for 14 days starting on day 1-3

    Also known as: Valtrex

  • Concomitant TMZ will be administered orally once a day at a dose of 75 mg/m2 starting the next day after completing prodrug and continued for 6 weeks. Adjuvant TMZ will be administered days 1 to 5 of a 28-day cycle for 6 cycles with 150 mg/m2 administered for cycle 1, and 150 to 200 mg/m2 administered for cycles 2 to 6. Adjuvant treatment will start 1 month following completing RT.

  • RadiationRadiation therapy

    Radiation will be administered to up-front patients as per standard of care for the patient. It will start 3-7 days after CAN-2409 injection, preferably closer to 3 days. It will consist of standard external field radiation, limited to the area of tumor and brain adjacent to tumor, fractionated at doses of 200cGy per day for approximately 6 weeks to a total of 5500-6000 cGy.

07

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Related Adverse Events

    Time frame: 2 months

Secondary outcomes

  1. Overall Survival

    Time frame: 5 years

Other outcomes

  1. Progression Free Survival

    Time frame: 24 months

  2. Functional Assessment of Cancer Therapy - Brain (FACT-Br)

    Time frame: 24 months

08

Results

Posted Apr 3, 2024

Participant flow

Enrollment to Treatment Initiation
Participant flow — Enrollment to Treatment Initiation
MilestoneSingle Arm
Started52
Completed43
Not completed9
Withdrew: Patients ineligable for study.9
Treatment Initiation to Completion
Participant flow — Treatment Initiation to Completion
MilestoneSingle Arm
Started43
Completed36
Not completed7
Withdrew: Treatment discontinuation7

Outcome measures

PrimaryNumber of Participants With Treatment Related Adverse Events
Time frame:
2 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment Related Adverse Events
ParticipantsSingle Arm
Number of Participants With Treatment Related Adverse Events21
SecondaryOverall Survival
Time frame:
5 years
Reported as:
Median · Months
Overall Survival
MonthsSingle Arm
Overall Survival18.15 (13.60 to 25.00)
Other pre-specifiedProgression Free Survival
Time frame:
24 months

Results for this outcome have not been posted.

Other pre-specifiedFunctional Assessment of Cancer Therapy - Brain (FACT-Br)
Time frame:
24 months

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events were assessed up to 2 months. All-Cause Mortality was assessed up to 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single Arm41/43 (95.3%)20/43 (46.5%)40/43 (93%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventSingle Arm
FeverGeneral disorders4/43
Thrombosis EmbolismVascular disorders4/43
Cerebral EdemaNervous system disorders3/43
SeizureNervous system disorders3/43
Cognitive DisturbanceNervous system disorders2/43
Mood Alteration - DepressionNervous system disorders2/43
ArrhythmiaCardiac disorders1/43
DehydrationGastrointestinal disorders1/43
PancreatitisHepatobiliary disorders1/43
Wound InfectionInfections and infestations1/43
Most frequent other events
Showing 10 of 26
Most frequent other events
EventSingle Arm
FatigueGeneral disorders22/43
HeadacheNervous system disorders21/43
SeizureNervous system disorders11/43
ConstipationGastrointestinal disorders9/43
Mood Alteration - DepressionNervous system disorders9/43
Speech ImpairmentNervous system disorders9/43
InsomniaGeneral disorders9/43
FeverGeneral disorders7/43
AnorexiaGastrointestinal disorders7/43
Memory ImpairmentNervous system disorders7/43

Baseline characteristics

All patient who initated experimental treatment in the study

Age, Categorical
Age, Categorical(Participants)Single Arm
<=18 years0
Between 18 and 65 years33
>=65 years10
Sex: Female, Male
Sex: Female, Male(Participants)Single Arm
Female13
Male30
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Single Arm
Hispanic or Latino6
Not Hispanic or Latino37
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Single Arm
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American0
White41
More than one race0
Unknown or Not Reported0
09

Study locations

4 sites
  • City of Hope Medical Center
    Duarte, California 91010, United States
  • The University of Chicago
    Chicago, Illinois 60637, United States
  • The Ohio State University Medical Center, Dept. Neurological Surgery
    Columbus, Ohio 43210, United States
  • The Methodist Hospital Neurological Institute
    Houston, Texas 77030, United States
10

References and documents

Publications

  • Wheeler LA, Manzanera AG, Bell SD, Cavaliere R, McGregor JM, Grecula JC, Newton HB, Lo SS, Badie B, Portnow J, Teh BS, Trask TW, Baskin DS, New PZ, Aguilar LK, Aguilar-Cordova E, Chiocca EA. Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. Neuro Oncol. 2016 Aug;18(8):1137-45. doi: 10.1093/neuonc/now002. Epub 2016 Feb 2. PubMed 26843484 ↗

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Dec 2015 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2024, 8 years 4 months after primary completion. A results delay was requested in Apr 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2007
First posted
Jan 10, 2008
Start
Mar 2007
Primary completionActual
Dec 2015
CompletionActual
Aug 2016
Results delay requested
Apr 8, 2017
Results first posted
Apr 3, 2024
Last update
Apr 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00589875
Lead sponsor
Candel Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jan 10, 2008
Start date
Mar 2007
Primary completion
Dec 2015
Completion
Aug 2016
Results posted
Apr 3, 2024
Last update
Apr 3, 2024

Study contacts

E. Antonio Chiocca, MD, PhD
principal investigator · Ohio State University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aglatimagene besadenovec

Start the discussion